Turning anonymous symptom descriptions into structured biological signals with OpenGenome
Official title: Accuracy and Calibration of Evidence-Grounded Biomedical Signal Extraction From Free-Text Symptom Descriptions: A Prospective Observational Registry Using the OpenGenome Automated Research Instrument
Run by OpenGenome · NCT07578610 · Data updated 2026-11-12
This project tries to turn adults' anonymous free-text symptom descriptions submitted to OpenGenome into structured, literature-grounded biological signals using PubMed and ClinicalTrials.gov sources and a constrained reasoning model.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 1000 (estimated) |
| Sponsor | OpenGenome Research network |
| Locations | 1 site (Friedrichshain, State of Berlin) |
| Status | Recruiting |
| Started | May 5, 2026 |
| Main results expected | May 5, 2028 |
| Study ends | May 30, 2028 |
| Registry record updated | May 19, 2026 |
| Trial ID | NCT07578610 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal participants are adults who voluntarily submit meaningful, health-related free-text symptom descriptions on the OpenGenome platform and are not automated or rate-limited submissions.
✕Probably not a fit
People seeking direct medical care, personalized treatment recommendations, minors, or submissions that are automated/contain no health-related content are unlikely to get benefit from this registry.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
OpenGenome collects anonymized free-text symptom descriptions from consenting adults and sends parallel queries to PubMed and ClinicalTrials.gov to retrieve up to 16 real sources per submission. A constrained reasoning model operating under a strict output schema extracts a primary biological signal, up to five secondary signals, a plain-language correlation explanation, and two integer scores (confidence and signal strength from 0–100). All outputs include source identifiers (PMID or NCT) that are directly linkable for independent verification, and no participant contact occurs. The registry analyzes aggregate anonymized outputs to characterize internal consistency of signals, calibration of confidence scores by dataset size and symptom specificity, and population-level distributions of biological signal categories.
Why it matters
Potential benefit: If successful, this could give people clearer, literature-linked summaries of what their symptoms might signal and help researchers and clinicians generate hypotheses faster.
How similar studies have gone: Related natural-language and knowledge-extraction efforts have shown promise, but the live linkage of each free-text submission to up-to-date PubMed and ClinicalTrials.gov sources under a strict schema is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
* Automated or programmatically generated submissions detected by rate limiting * Submissions containing no discernible symptom or health-related content
Where it's running
-
OpenGenome
Friedrichshain, State of Berlin, Germany Recruiting
Study contacts
- Study coordinator: Richard Koch
- Email: richard@opengenome.bio
- Phone: +491634168231
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
See if Buzzy and virtual reality help kids get IV lines faster
This study tests whether a vein-imaging device plus virtual reality or the same device plus a pain-reducing tool can make peripheral IV placement easier for children aged 7–12 with fever.
-
Does driving with UVA exposure affect facial skin hydration on the left vs right cheek in Florida drivers
This observational study tests whether Florida women who drive more show less hydration on their left cheek (exposed to UVA through the driver-side window) compared with their right cheek.
-
Triage performance and physiological predictors of serious illness in febrile children in the pediatric emergency department
This study tests whether the initial color-coded triage category and vital signs at triage can predict serious outcomes in febrile children who come to pediatric emergency departments in Turkey.
-
Topical KB111 for Hailey-Hailey Disease (early phase, kids and adults)
This study tests whether a topical KB111 treatment is safe and helps with lesions in people with Hailey-Hailey disease, including adolescents and adults.
-
Selective activation of the adrenomedullin receptor to provoke migraine in adults with migraine without aura
This study tests whether selectively activating the adrenomedullin receptor can trigger migraine attacks in adults who have migraine without aura, after blocking CGRP receptors.
-
Safety of BG-A3004 in healthy volunteers and people with immune-mediated skin diseases
This study will test whether single and multiple doses of the experimental drug BG-A3004 are safe and how the body handles it in healthy adults and people with immune-mediated skin diseases.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.